NGL Fine-Chem Limited

NGLFINE

INE887E01022

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:49 2024-04-29 am EDT			5-day change	1st Jan Change
2,534 ^INR	-4.01%		-0.43%	+13.55%

Apr. 19	NGL Fine-Chem Limited Approves the Appointment of Dhananjay Mungale as Independent Director	CI
Mar. 29	Crisil Keeps NGL Fine-Chem Rating at BBB+; Outlook Stable	MT

NGL Fine-Chem Limited Announces Retirement of Milind Shinde as Independent Director, with Effect from March 31, 2024

March 28, 2024 at 07:32 am EDT

NGL Fine-Chem Limited announced the retiremrnt of Mr. Milind Shinde as Independent Director of the Company on March 31, 2024, due to completion of second term of office as an Independent Director. Consequently, he will cease to be a Director of the Company with effect from close of business hours on March 31, 2024.

Latest news about NGL Fine-Chem Limited

NGL Fine-Chem Limited Approves the Appointment of Dhananjay Mungale as Independent Director	Apr. 19	CI
Crisil Keeps NGL Fine-Chem Rating at BBB+; Outlook Stable	Mar. 29	MT
NGL Fine-Chem Limited Announces Retirement of Milind Shinde as Independent Director, with Effect from March 31, 2024	Mar. 28	CI
NGL Fine-Chem Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Transcript : NGL Fine-Chem Limited, Q2 2024 Earnings Call, Nov 20, 2023	Nov. 20
NGL Fine-Chem Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-04	CI
Crisil Keeps SME 1 Rating on NGL Fine-Chem	23-07-18	MT
Transcript : NGL Fine-Chem Limited, Q4 2023 Earnings Call, May 19, 2023	23-05-19
NGL Fine-Chem Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-15	CI
NGL Fine-Chem Limited Recommends Final Dividend for the Financial Year Ended on March 31, 2023, Payable on or After September 4, 2023	23-05-15	CI
ICRA Affirms NGL Fine-Chem Rating at BBB+	23-03-30	MT
NGL Fine-Chem Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-10	CI
Crisil Keeps NGL Fine-Chem Rating at BBB+; Lowers Outlook to Stable	23-01-11	MT
Transcript : NGL Fine-Chem Limited, Q3 2022 Earnings Call, Nov 17, 2022	22-11-17
NGL Fine-Chem Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-10-28	CI
Transcript : NGL Fine-Chem Limited, Q1 2023 Earnings Call, Aug 17, 2022	22-08-17
NGL Fine-Chem Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-11	CI
NGL Fine-Chem Limited Announces Resignation of K.V. Subramanian as Independent Director	22-08-10	CI
NGL Fine-Chem Limited Approves Final Dividend for the Financial Year Ended 31 March, 2022	22-07-01	CI
Crisil Keeps SME 1 Rating on NGL Fine-Chem; Shares Fall 5%	22-06-20	MT
Transcript : NGL Fine-Chem Limited, Q4 2022 Earnings Call, May 04, 2022	22-05-04
NGL Fine-Chem Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	22-05-02	CI
NGL Fine-Chem Limited Recommends Final Dividend for the Financial Year Ended on 31 March 2022	22-05-02	CI
Crisil Affirms NGL Fine-Chem's Rating at BBB+; Outlook Positive	22-04-12	MT
Crisil Keeps BBB+ Rating on NGL Fine-Chem; Raises Outlook to Positive	22-02-28	MT

Chart NGL Fine-Chem Limited

Duration

Period

More charts

Company Profile

NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
NGL FINE-CHEM LIMITED	+13.55%	196M
ZOETIS INC.	-19.09%	72.39B
ELANCO ANIMAL HEALTH INCORPORATED	-8.93%	6.54B
BLUESTAR ADISSEO COMPANY	+21.38%	3.43B
VIMIAN GROUP AB	+1.52%	1.4B
JINYU BIO-TECHNOLOGY CO., LTD.	-16.99%	1.34B
VETOQUINOL SA	-3.81%	1.26B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-26.05%	1.2B
WUHAN KEQIAN BIOLOGY CO.,LTD	-12.71%	1.12B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-4.03%	990M